Principal Securities’s Ascendis Pharma A/S ASND Stock Holding History

Principal Securities’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Buy	+1,132	New	+$264K	﹤0.01%	1323
2025 Q4	–	Sell	-87	Closed	-$17.3K	–	1488
2025 Q3	$17.3K	Buy	87 +80	+1,143%	+$14.9K	﹤0.01%	2467
2025 Q2	$1.21K	Buy	7 +1	+17%	+$163	﹤0.01%	3288
2025 Q1	$826	Hold	6	–	–	﹤0.01%	3255
2024 Q4	$826	Hold	6	–	–	﹤0.01%	3248
2024 Q3	$896	Buy	+6	New	+$810	﹤0.01%	3161

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Principal Securities's ASND Position: Q2 2026 in Review

Principal Securities opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 1,132 shares worth $302K. The stake represents ﹤0.01% of the portfolio and ranks #1323 among its holdings. This is a return to the name: Principal Securities previously reported a position in ASND as recently as Q3 2025.

Principal Securities first reported a position in ASND in Q3 2024 and has held it in 6 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Principal Securities held 1,132 shares of Ascendis Pharma A/S worth $302K as of Q2 2026.
Ascendis Pharma A/S was a new Principal Securities position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Principal Securities's portfolio in Q2 2026, its #1323 holding.
Principal Securities first reported a position in Ascendis Pharma A/S in Q3 2024 and has held it in 6 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.